Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 492 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR New Study Finds Dogs Can Sniff Out Lung Cancer — And... April 10, 2019 ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) February 7, 2019 An Oncology Hospital at Home Model of Acute Care Shows Promise May 21, 2021 Epigenetic Changes Pinpointed as the Cause of Some GISTs November 19, 2019 Load more HOT NEWS Scientists developing urine and blood tests to detect brain tumours FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid... EMA Recommends Extension of Therapeutic Indications for Cabozantinib EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab
